LifePoint Health, Inc. (LPNT) Downgraded to Sell at Zacks Investment Research
Zacks Investment Research cut shares of LifePoint Health, Inc. (NASDAQ:LPNT) from a hold rating to a sell rating in a research note published on Tuesday morning.
According to Zacks, “LifePoint Health’s stock has underperformed the industry in last three months. The company is faced with increasing expenses which has outpaced revenue growth thereby squeezing operating margins. The company is suffering from low patient admissions. High bad debt is another concern. Following second-quarter results, the company trimmed its 2017 guidance on a challenging volume environment and weak revenue growth. The stock has seen the Zacks Consensus Estimate for current-year earnings being revised 2.9% downward over the last 60 days.”
LPNT has been the subject of several other reports. ValuEngine raised shares of LifePoint Health from a hold rating to a buy rating in a research note on Thursday, August 17th. BidaskClub lowered shares of LifePoint Health from a hold rating to a sell rating in a report on Tuesday, August 1st. Morgan Stanley began coverage on LifePoint Health in a research note on Tuesday, June 6th. They issued an equal weight rating and a $65.00 target price on the stock. TheStreet downgraded LifePoint Health from a b- rating to a c+ rating in a report on Wednesday, August 16th. Finally, Royal Bank Of Canada restated a buy rating and set a $77.00 price target on shares of LifePoint Health in a report on Wednesday, July 5th. Four analysts have rated the stock with a sell rating, nine have given a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $66.40.
LifePoint Health (NASDAQ:LPNT) traded down 1.402% during midday trading on Tuesday, hitting $58.025. 188,520 shares of the stock traded hands. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 12.993 and a beta of 0.84. The stock’s 50-day moving average price is $56.96 and its 200 day moving average price is $61.39. LifePoint Health has a 52 week low of $50.60 and a 52 week high of $70.95.
LifePoint Health (NASDAQ:LPNT) last announced its quarterly earnings results on Tuesday, August 1st. The company reported $0.96 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.90 by $0.06. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.64 billion. LifePoint Health had a net margin of 2.61% and a return on equity of 7.40%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.69 EPS. On average, equities research analysts predict that LifePoint Health will post $4.06 EPS for the current year.
ILLEGAL ACTIVITY WARNING: “LifePoint Health, Inc. (LPNT) Downgraded to Sell at Zacks Investment Research” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/lifepoint-health-inc-lpnt-downgraded-to-sell-at-zacks-investment-research/1608386.html.
In related news, Chairman William F. Carpenter III sold 17,653 shares of LifePoint Health stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $65.06, for a total transaction of $1,148,504.18. Following the sale, the chairman now directly owns 439,841 shares in the company, valued at $28,616,055.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.76% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its position in LifePoint Health by 11,671.9% during the first quarter. BlackRock Inc. now owns 3,745,824 shares of the company’s stock valued at $245,351,000 after buying an additional 3,714,004 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of LifePoint Health by 0.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 3,388,830 shares of the company’s stock valued at $221,969,000 after buying an additional 18,327 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of LifePoint Health by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 3,310,467 shares of the company’s stock valued at $222,299,000 after buying an additional 43,504 shares in the last quarter. LSV Asset Management boosted its holdings in shares of LifePoint Health by 83.5% during the 2nd quarter. LSV Asset Management now owns 1,994,557 shares of the company’s stock valued at $133,934,000 after buying an additional 907,469 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of LifePoint Health by 2.1% during the 2nd quarter. State Street Corp now owns 1,132,914 shares of the company’s stock valued at $76,075,000 after buying an additional 23,552 shares in the last quarter. Institutional investors and hedge funds own 99.53% of the company’s stock.
LifePoint Health Company Profile
LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers and post-acute facilities. As of December 31, 2016, the Company operated 72 hospital campuses in 22 states, having a total of 9,424 licensed beds. It offers a range of general and specialized healthcare services to patients through a network of hospitals and outpatient facilities.
Receive News & Ratings for LifePoint Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.